Dimensional Fund Advisors LP Boosts Stake in Bausch Health Companies Inc. (NYSE:BHC)

Dimensional Fund Advisors LP increased its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,113,107 shares of the company's stock after buying an additional 90,166 shares during the quarter. Dimensional Fund Advisors LP owned about 0.86% of Bausch Health Companies worth $25,089,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in shares of Bausch Health Companies by 1,246.0% during the fourth quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company's stock valued at $160,000 after buying an additional 18,366 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after buying an additional 1,263,706 shares during the last quarter. Range Financial Group LLC purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at $1,004,000. Vanguard Group Inc. grew its holdings in shares of Bausch Health Companies by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock valued at $94,460,000 after buying an additional 145,078 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at $180,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Stock Up 4.9%

Shares of BHC stock traded up $0.23 during mid-day trading on Monday, hitting $4.82. 1,897,701 shares of the stock were exchanged, compared to its average volume of 2,628,045. The firm has a fifty day moving average of $5.79 and a 200 day moving average of $7.09. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $9.85. The company has a market cap of $1.74 billion, a PE ratio of -40.29, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Equities analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BHC shares. StockNews.com lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Saturday. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Finally, Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. According to MarketBeat.com, Bausch Health Companies currently has an average rating of "Hold" and an average price target of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.